Tango Therapeutics (TNGX) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $15.9 million.
- Tango Therapeutics' Income towards Parent Company rose 15445.88% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 1856.67%. This contributed to the annual value of -$130.3 million for FY2024, which is 2806.85% down from last year.
- Tango Therapeutics' Income towards Parent Company amounted to $15.9 million in Q3 2025, which was up 15445.88% from -$38.9 million recorded in Q2 2025.
- In the past 5 years, Tango Therapeutics' Income towards Parent Company registered a high of $15.9 million during Q3 2025, and its lowest value of -$39.9 million during Q1 2025.
- Over the past 5 years, Tango Therapeutics' median Income towards Parent Company value was -$25.6 million (recorded in 2024), while the average stood at -$24.3 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 95180677.97% in 2021, then soared by 15445.88% in 2025.
- Over the past 5 years, Tango Therapeutics' Income towards Parent Company (Quarter) stood at -$22.1 million in 2021, then plummeted by 31.98% to -$29.1 million in 2022, then dropped by 5.65% to -$30.8 million in 2023, then dropped by 22.37% to -$37.6 million in 2024, then skyrocketed by 142.21% to $15.9 million in 2025.
- Its last three reported values are $15.9 million in Q3 2025, -$38.9 million for Q2 2025, and -$39.9 million during Q1 2025.